7 results about "Viral Inactivation" patented technology

The application discloses a natural recombination novel duck reovirus variant (NDRV-GXNN-2025) strain, which has a preservation number of CCTCC No:V202613 and a preservation date of January 28, 2026. Researches show that the NDRV-GXNN-2025 strain has high pathogenicity to ducklings and goslings, and the mortality rates of 2-day-old ducklings and goslings are 30% and 50% respectively when the attack dose is 104.0 / 0.1ml; meanwhile, the strain has good immunogenicity and is an ideal vaccine candidate strain. Accordingly, the inventors also establish a preparation method of a corresponding inactivated vaccine. The novel duck reovirus inactivated vaccine prepared by the method has good stability and safety, can induce the body to produce high-level neutralizing antibodies after immunizing ducklings and goslings, and can effectively resist the attack of the novel duck reovirus variant, and has a good application prospect.

The present invention provides intravenous pharmaceutical compositions comprising engineered plant virus-based nanoparticles for the treatment or prevention of autoimmune conditions. The nanoparticles display immunodominant peptides that induce immune tolerance in a subject when administered intravenously. The invention further provides methods of manufacturing virus-based nanoparticles, including production in plant expression systems and optional viral inactivation, to render them suitable for therapeutic use in mammals. Also provided are methods of intravenous administration of the pharmaceutical compositions to a subject in need thereof for treating or preventing autoimmune conditions.

This invention discloses a data-driven modeling and predictive control method for respiratory virus inactivation, relating to the field of biomedical technology. The method includes the following steps: obtaining initial viral characteristic data from a viral surface structure database through molecular dynamics simulation, processing the data to obtain a structural change matrix of the virus under different inactivation conditions; using a support vector machine classifier based on the structural change matrix to extract features of viral characteristics and antibody binding sites, determining a set of potential unexpected interaction sites. This data-driven modeling and predictive control method for respiratory virus inactivation effectively improves the scientific validity and stability of inactivation process parameters, reduces safety risks caused by improper inactivation conditions, shortens the process optimization cycle, reduces experimental costs, and helps maintain good immunogenicity while ensuring the safety of virus inactivation, thereby better meeting the practical application needs in vaccine development and virus prevention and control.

The present application relates to a kind of non-guanidine salt type compatible nucleic acid extraction virus preservative and preparation method and application, the virus preservative, including P (HEMA-BAMPD) hydrochloride, buffer, chelating agent, saccharide stabilizer and osmotic pressure regulator.The present application replaces guanidine salt and small molecule quaternary ammonium salt with P (HEMA-BAMPD) hydrochloride, and the inactivation rate effect of SARS-CoV-2 virus, influenza virus and other envelope type RNA / DNA viruses is good, and there is no irritability, and it is friendly to operating personnel and environment;Polymer structure realizes multiple point adsorption, and the ability of resistance to organic interference is strong, and a small amount of blood, sputum and other components in sample do not affect inactivation effect.Moreover, P (HEMA-BAMPD) hydrochloride, chelating agent and saccharide stabilizer synergistic effect can effectively inhibit RNase, DNase activity.

A culture chamber that can be provided in a modular form to provide flexibility in the flow rate and / or residence time of a product stream is disclosed. An assembly comprising such a culture chamber for the purification of biomolecules is also disclosed, as well as a method for the purification of biomolecules, and in particular a method for inactivating viruses in a culture chamber or a plurality of culture chambers arranged in series.

An improved technology for inactivation of viruses, for example the SARS-COV-2 virus that is causing the Covid-19 pandemic, is described. The technology can include a device that includes a substrate coated in a polymer that is infused with a pathogen inactivating material. In various embodiments, at a given time, a portion of the pathogen inactivating material is exposed to the environment, and the device is configured to periodically or intermittently expose additional pathogen inactivating material to the environment. For example, the polymer can be ablative or sacrificial.

The virus inactivation compound according to the present invention is a compound represented by formula (1) or formula (2). (In formula (1), n is an integer of 3-19, and in formula (2), m is an integer of 3-19). The present invention makes it possible to provide a virus inactivation compound having an excellent virus inactivation effect.